Microglia and Alzheimer's Disease.

Area of Science:

• Neuroscience
• Immunology
• Pathology

Background:

• Alzheimer's disease (AD) urgently requires novel therapeutic and preventative strategies.
• Microglia, the brain's primary immune cells, are central to AD pathogenesis and neuroinflammation.
• Microglial function declines in later AD stages due to chronic inflammation and amyloid-beta (Aβ) accumulation.

Purpose of the Study:

• To explore the multifaceted roles of microglia in Alzheimer's disease.
• To understand the mechanisms underlying microglial dysfunction and neuroinflammation in AD.
• To highlight the need for biomarkers and immunomodulatory therapies for AD.

Main Methods:

• Review of microglial activation pathways in response to AD pathology (amyloid-beta and tau).
• Analysis of inflammatory signaling cascades (NF-kB, JAK-STAT, NLRP3 inflammasome) in microglia.
• Examination of factors contributing to microglial impairment, including oxidative stress and iron overload.

Main Results:

• Microglia activation by amyloid-beta and tau can be protective but leads to detrimental neuroinflammation in chronic AD.
• Sustained microglial activation contributes to oxidative stress, iron overload, and neurotoxicity.
• The diverse functions of microglia necessitate the development of specific biomarkers for their activity.

Conclusions:

• Developing immunomodulatory therapies to restore physiological microglial function is imperative for AD treatment.
• Comprehending microglial impairment mechanisms is key to advancing AD therapeutics.
• Targeting neuroinflammation and enhancing microglial protective roles offer promising avenues for AD intervention.